Related Experiment Video

Updated: Aug 11, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Strategies for management and treatment of dyslipidemia in HIV/AIDS

P E Sax1

  • 1Division of infection, Diseases and HIV Program, Brigham and Women's Hospital, Boston, MA 02115, USA. psax@partners.org

AIDS Care
|December 13, 2005
PubMed

Insights

HIV patients on protease inhibitor (PI) therapy often develop dyslipidemia, a cardiovascular risk. Lifestyle changes are recommended, but some patients require PI modification or lipid-lowering drugs to manage abnormal lipid levels while maintaining viral suppression.

Area of Science:

  • Internal Medicine
  • Cardiology
  • Infectious Diseases

Background:

  • Improved survival in HIV-infected patients has led to concerns about long-term treatment effects.
  • Protease inhibitors (PIs) in combination antiretroviral therapy (ART) are associated with dyslipidemia in 50-70% of patients.
  • Elevated cholesterol and triglycerides are significant risk factors for cardiovascular disease.

Purpose of the Study:

  • To review the management of dyslipidemia in HIV-infected patients on PI-based ART.
  • To discuss the balance between managing lipid abnormalities and maintaining viral suppression.

Main Methods:

  • Literature review of studies on HIV dyslipidemia and its management.
  • Analysis of treatment strategies including lifestyle modifications, PI changes, and lipid-lowering drugs.

Main Results:

  • Lifestyle modifications (diet, exercise, reduced alcohol, smoking cessation) are initial recommendations.
  • Many patients require further intervention, such as switching PIs or using lipid-lowering medications.
  • Successful management requires balancing lipid control with sustained viral suppression.

Conclusions:

  • HIV dyslipidemia is a common and serious complication of PI-based ART.
  • A multi-faceted approach is necessary, often involving pharmacologic interventions.
  • Careful consideration of treatment options is crucial to optimize patient outcomes.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...